Skip to main content
METABIOMED.CO.,LTD logo

METABIOMED.CO.,LTD — Investor Relations & Filings

Ticker · 059210 ISIN · KR7059210005 KO Manufacturing
Open in API
Filings indexed 217 across all filing types
Latest filing 2024-03-15 Transaction in Own Shar…
Country KR South Korea
Listing KO 059210

About METABIOMED.CO.,LTD

https://www.meta-biomed.com/

METABIOMED.CO.,LTD. is a developer and manufacturer of medical devices and biomaterials. The company's operations are organized into four primary business areas: Dental, Suture Material & Biomaterial, Meta Surgical, and Cosmetic Medical. Its dental division provides a range of equipment and materials, with its root canal filling product holding the largest global market share. The company also manufactures various synthetic absorbable surgical sutures, including Poliglecaprone (PGCL) and Polydioxanone (PDO) types. The surgical division offers devices for use in general surgery, orthopedics, neurosurgery, and obstetrics & gynecology. In the cosmetic medical field, it produces products such as PDO threads. METABIOMED distributes its products to over 100 countries through a global sales network.

Recent filings

Filing Released Lang Actions
[연장결정]주요사항보고서(자기주식취득신탁계약체결결정)
Transaction in Own Shares Classification · 100% confidence The document is a 'Major Report' (주요사항보고서) filed with the Korean financial authorities (Financial Services Commission/Korea Exchange) regarding the extension of a trust agreement for the acquisition of treasury shares (자기주식취득 신탁계약 연장결정). This type of filing is a specific regulatory disclosure concerning a company's capital structure and share repurchase activities. According to the provided definitions, 'Transaction in Own Shares' (POS) is the most accurate category for reports detailing share buybacks or related trust agreements.
2024-03-15 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 100% confidence The document is a regulatory filing from Meta Biomed regarding a significant change (over 15-30%) in revenue or profit structure. This is a standard Korean regulatory disclosure (DART filing) for financial performance updates. Since it provides specific financial highlights and reasons for the change rather than being a full annual report or a simple announcement of a report's availability, it falls under the category of Earnings Release (ER) as it serves as the initial announcement of financial results. FY 2023
2024-03-14 Korean
현금ㆍ현물배당결정
Notice of Dividend Amount Classification · 100% confidence The document is a formal announcement from Meta Biomed regarding the decision to pay cash dividends. It specifies the dividend amount per share, the dividend record date, the payment date, and the approval process via the upcoming general meeting of shareholders. This aligns perfectly with the definition of a 'Notice of Dividend Amount' (DIV).
2024-03-14 Korean
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) issued by Meta Biomed. It outlines the date, location, and specific agenda items for the upcoming Annual General Meeting, including the approval of financial statements, dividend declarations, and the election of directors and auditors. This type of document is provided to shareholders to solicit their participation and votes, fitting the definition of a Proxy Solicitation & Information Statement.
2024-03-14 Korean
주주총회집중일개최사유신고
AGM Information Classification · 98% confidence The document is a formal regulatory filing submitted to the KOSDAQ exchange regarding the scheduling of a General Meeting of Shareholders on a 'concentrated date' (a date when many companies hold their meetings). It explains the operational reasons for this scheduling, such as consolidated financial reporting and auditor availability. Since it is a regulatory disclosure regarding meeting logistics rather than the meeting materials themselves or the voting results, it falls under the general regulatory filing category.
2024-03-14 Korean
주주총회소집공고
AGM Information Classification · 98% confidence The document is a 'Notice of Annual General Meeting' (주주총회소집공고) for Meta Biomed. It contains the meeting agenda, details on voting procedures, and financial statements (balance sheet, income statement) for the 25th fiscal year. While it contains financial data, it is primarily a proxy statement/notice for shareholders to attend the AGM and vote on agenda items, which fits the definition of a Proxy Solicitation & Information Statement (PSI).
2024-03-14 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.